脾切除联合门奇静脉断流术治疗乙型肝炎肝硬化门脉高压症患者疗效研究*

doi:10.3969/j.issn.1672-5069.2021.05.011

摘要/Abstract

摘要： 目的探讨采用脾切除(SPL)联合门奇静脉断流术(PAD)治疗乙型肝炎肝硬化门脉高压症患者的临床疗效。方法 2017年2月～2019年11月我院诊治的87例乙型肝炎肝硬化门脉高压症患者,其中45例接受SPL联合PAD治疗(观察组),另42例接受胃底曲张静脉栓塞术和部分脾栓塞术(对照组)。测量上臂围和三头肌皮褶厚度,使用多普勒超声诊断仪检测门静脉血流量(PVF)、肠系膜上静脉血流量(SMVF)和脾静脉血流量(SVF)。结果术后,观察组BMI、上臂围和三头肌皮褶厚度分别为(21.5±1.3)kg/m²、(22.1±1.0)cm和(10.3±1.0)mm,与对照组【分别为(21.2±1.2)kg/m²、(22.2±1.2)cm和(10.1±1.1)mm,P>0.05】比,无显著性差异;术后1个月,观察组PVF和SMVF分别为(670.9±46.2)ml/min和(583.5±69.0)ml/min,与对照组【分别为(695.7±50.2)ml/min和(540.2±68.4)ml/min,P<0.05】比,差异显著;观察组血清ALB水平为(34.0±1.4)g/L,显著高于对照组【(31.2±1.5)g/L,P<0.05】;观察组并发症发生率为8.9%,显著低于对照组的38.1%(P<0.05)。结论经典的脾切除联合门奇静脉断流术治疗乙肝肝硬化门脉高压症患者有效,降低了门脉压力,改善了肝脏血流灌注和肝功能,提高了营养状态。

关键词: 肝硬化, 门脉高压症, 脾切除术, 门奇静脉断流术, 治疗

Abstract: Objective The aim of this study was to re-observe the clinical efficacy of splenectomy (SPL) and portal-azygous disconnection (PAD) in treating patients with hepatitis B cirrhosis and portal hypertension. Methods A total of 87 patients with hepatitis B cirrhosis and portal hypertension were enrolled in our hospital between Februar y 2017 and November 2019, and 45 patients out of them received SPL and esophagogastric devascularization (observation group) and 42 patients underwent percutaneous transhepatic variceal embolization ( PTVE) and partial splenic embolization. The body mass index (BMI), mid-upper arm circumference (MUAC) and riceps skinfold thickness (RST) were measured. The portal venous flow (PVF), superior mesenteric venous flow (SMVF) and splenic venous flow ( SVF) were measured by sonography. Results One month after operation, the BMI, MUAC and RST in the observation were (21.5±1.3)kg/m², (22.1±1.0)cm and (10.3±1.0)mm, not significantly different as compared to in the control; the PVF and SMVF were (670.9±46.2)ml/min and (583.5±69.0)ml/min, significantly different compared to in the control; serum albumin levels was (34.0±1.4)g/L, significantly higher than in the control; the incidence of post-operational complications was 8.9%, much lower than 38.1%(P<0.05) in the control. Conclusion The classic splenectomy and esophagogastric devascularization combination is still an important choice of treatment for patients with hepatitis B cirrhosis and portal hypertension, which might reduce the portal pressure, improve liver function and liver blood perfusion with fewer complications.

Key words: Liver cirrhosis, Portal hypertension, Splenectomy, Esophagogastric devascularization, Therapy

刘公伟, 吴雪, 唐聃, 敖宇, 陈景祥, 蔡治方. 脾切除联合门奇静脉断流术治疗乙型肝炎肝硬化门脉高压症患者疗效研究^*[J]. 实用肝脏病杂志, 2021, 24(5): 649-652.

Liu Gongwei, Wu Xue, Tang Dan, et al. Re-observation of splenectomy and esophagogastric devascularization in patients with hepatitis B cirrhosis and portal hypertension[J]. Journal of Practical Hepatology, 2021, 24(5): 649-652.

参考文献

[1]常伟华,李志伟,张昆,等.脾部分切除联合门奇静脉断流术对巨脾患者门静脉血栓形成的预防作用.中华肝胆外科杂志,2018,24(12):843-847.
[2]Lu C L, Cao Y J, Cheng H, et al. Clinical factors that influence the outcome of selective devascularization in the treatment of portal hypertension. Oncotarget, 2016, 7(31):50635-50642.
[3]Zheng S, Sun P, Liu X, et al. Efficacy and safety of laparoscopic splenectomy and esophagogastric devascularization for portal hypertension: A single-center experience. Medicine, 2018, 97(50):e13703.
[4]王贵强,王福生,成军,等.慢性乙型肝炎防治指南(2015年版).中华实验和临床感染病杂志(电子版),2015,19(5):1-8.
[5]中华医学会外科学分会门静脉高压症学组.肝硬化门静脉高压症食管,胃底静脉曲张破裂出血诊治专家共识(2015年).中国实用外科杂志,2015,35(10):1086-1090.
[6]Wu H, Yan S, Wang G, et al. von Willebr and factor as a novel noninvasive predictor of portal hypertension and esophageal varices in hepatitis B patients with cirrhosis. Scand J Gastroenterol, 2015, 50(9):1160-1169.
[7]Wang Y, Ma L, Yuan Z, et al. Correction: Percutaneous thermal ablation combined with TACE versus TACE monotherapy in the treatment for liver cancer with hepatic vein tumor thrombus: A retrospective study. PLoS ONE, 2018, 13(9):e204535.
[8]刘琴,罗艳丽,肖凤鸣,等.乙型肝炎肝硬化门脉高压症行脾切除联合门奇静脉断流术后影响预后的因素分析.实用肝脏病杂志,2017,20(6):769-770.
[9]Wang M, Ding L, Xu M, et al. A novel method detecting the key clinic factors of portal vein system thrombosis of splenectomy & cardia devascularization patients for cirrhosis & portal hypertension. BMC Bioinformatics, 2019, 20(22):720.
[10] 阿思根,夏医君,武慧军,等.脾切除术联合门奇静脉断流术治疗肝硬化门脉高压症患者疗效研究.实用肝脏病杂志,2020,23(2):248-251.
[11] Chialà C, Venon W D, Tucci A, et al. Liver stiffness based model predicts portal hypertension, esophageal varices and hepatocellular carcinoma in Caucasian patients with hepatitis B virus-related cirrhosis responsive to antiviral therapy. J Hepatol, 2017, 66(1):S234.
[12] Haibo H, Chu XL, Wei SF, et al. Long-term efficacy of subtotal splenectomy due to portal hypertension in cirrhotic patients. Bmc Surg, 2015, 24(15):89.
[13] Zong GQ, Fei Y, Liu RM. Comparison ofeffects of devascularization versus shunt on patients with portal hypertension: A Meta-analysis. Hepatogastroenterology, 2015, 62(137):144-150.
[14] 胡景岚,唐建荣,付雪琴.乙型肝炎肝硬化患者在断流术前后接受阿德福韦酯联合恩替卡韦治疗生存期观察.实用肝脏病杂志,2017,20(5):616-617.
[15] Han X, Lv Y, Li Y, et al. Distribution characteristics of cells in splenomegaly due to hepatitis B-related cirrhotic portal hypertension and their clinical importance. J Int Med Res, 2018, 46(7):2633-2640.
[16] Zhang YF, Ji H, Lu HW, et al. Postoperative survival analysis and prognostic nomogram model for patients with portal hypertension. World J Gastroenterol, 2018, 24(39):4499-4509.
[17] 曾道炳,张纯,邸亮,等.脾切除联合门奇静脉断流术对肝硬化合并门静脉高压症患者近远期营养状况的影响.中华肝胆外科杂志, 2017,23(7):437-440.
[18] Wang Z, Zhao H, Wang X, et al. Clinical outcome comparison between TIPS and EBL in patients with cirrhosis and portal vein thrombosis. Abdom Imaging, 2015, 40(6):1813-1820.
[19] 柏斗胜,赵伟,蒋国庆,等.同步腹腔镜肝切除联合脾切除术治疗原发性肝癌并发肝硬化门静脉高压性脾功能亢进.中华消化外科杂志,2015,14(9):750-754.
[20] Al-Mahtab M, Bazinet M, Vaillant A. Safety andefficacy of nucleic acid polymers in monotherapy and combined with immunotherapy in treatment-naive Bangladeshi patients with HBeAg⁺ chronic hepatitis B infection. PLoS One, 2016, 11(6):e0156667.
[21] Vorobioff JD, Groszmann RJ. Prevention of portal hypertension: from variceal development to clinical decompensation. Hepatology, 2015, 61(1):375-381.
[22]吴武军,于咏田,杜立学,等.脾腔小口径分流联合断流术对肝硬化门静脉高压症患者肝血流动力学和储备功能的影响.实用肝脏病杂志,2016,19(2)(2):196-199.

脾切除联合门奇静脉断流术治疗乙型肝炎肝硬化门脉高压症患者疗效研究^*

Re-observation of splenectomy and esophagogastric devascularization in patients with hepatitis B cirrhosis and portal hypertension

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	汤磊, 邹桂舟. 外科疾病导致的胆源性肝损伤诊治现状[J]. 实用肝脏病杂志, 2021, 24(6): 769-771.
[2]	姜浩, 张雯, 陈霞. 长效干扰素联合利巴韦林治疗慢性丙型肝炎患者疗效及其对静息能量消耗和营养状态的影响^*[J]. 实用肝脏病杂志, 2021, 24(6): 815-818.
[3]	黄飞虎, 薛建亚, 朱咏梅, 余姣, 王丽艳, 鲁琼. 应用索磷布韦/维帕他韦治疗门诊和住院筛查的丙型肝炎患者疗效研究[J]. 实用肝脏病杂志, 2021, 24(6): 819-822.
[4]	肖金玉, 王延峰, 文小霞. 自身免疫性肝炎患者血清趋化因子CCL4和CXCL10水平及其临床意义探讨[J]. 实用肝脏病杂志, 2021, 24(6): 827-830.
[5]	杜云飞, 刘景瑞, 叶飞翔. N-乙酰半胱氨酸联合双环醇治疗抗结核药物所致的药物性肝损伤患者疗效研究^*[J]. 实用肝脏病杂志, 2021, 24(6): 847-850.
[6]	吴晓枫, 黄怡, 杨如杏, 邓少东, 张静莹, 官成浓, 王颖. 原发性胆汁性肝硬化患者外周血丝氨酸蛋白酶抑制剂A1基因多态性分析^*[J]. 实用肝脏病杂志, 2021, 24(6): 855-858.
[7]	石翠翠, 刘彦君, 章瑞南, 李光明, 范建高. 肝硬化患者血脂异常分析^*[J]. 实用肝脏病杂志, 2021, 24(6): 859-862.
[8]	柳梅, 时永红, 郇娟, 陈茂丽. 失代偿期肝硬化患者并发医院内感染病原菌类别及其耐药特点分析^*[J]. 实用肝脏病杂志, 2021, 24(6): 863-866.
[9]	刘玉玲, 甄增国, 王慧娟, 万秀敏, 郭振凯. 益生菌制剂对肝硬化并发自发性细菌性腹膜炎患者肠道屏障功能的影响^*[J]. 实用肝脏病杂志, 2021, 24(6): 867-870.
[10]	邢莉, 杜倩影, 姜艳丽, 韩冬. 分段注射对比剂CT增强扫描提高乙型肝炎肝硬化患者肝静脉显影效果研究^*[J]. 实用肝脏病杂志, 2021, 24(6): 871-874.
[11]	黄力鸥, 吴春荣, 徐丹, 崔宇慧, 唐建国. 无肝素化连续性肾脏替代治疗肝硬化并发肝性脑病患者疗效研究^*[J]. 实用肝脏病杂志, 2021, 24(6): 875-878.
[12]	叶东, 张俊霞, 李洁, 刘颖, 张丹, 郭永泽. 内镜下食管静脉曲张套扎术治疗乙型肝炎肝硬化并发食管胃底静脉曲张破裂出血患者再出血风险观察^*[J]. 实用肝脏病杂志, 2021, 24(6): 879-882.
[13]	韩成美, 韩永峰, 王春华. 乙型肝炎肝硬化患者并发急性肾损伤危险因素分析^*[J]. 实用肝脏病杂志, 2021, 24(6): 883-886.
[14]	王菁, 毕宁, 方亮, 田园. 自体骨髓干细胞经肝动脉肝内移植治疗失代偿期乙型肝炎肝硬化患者疗效研究[J]. 实用肝脏病杂志, 2021, 24(6): 887-890.
[15]	薛魁, 徐银海, 张健. 慢性乙型肝炎和乙型肝炎肝硬化患者血清血小板生成素水平变化及其临床意义^*[J]. 实用肝脏病杂志, 2021, 24(6): 891-894.